MedTrace Logo

A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

NCT06142383 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2026-01-27

Study results available
· View outcomes & findings →

Summary

This was a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.

Conditions

Interventions

BIOLOGICAL

Placebo

S.C. Injection

BIOLOGICAL

XXB750 Low dose

S.C. Injection

BIOLOGICAL

XXB750 Medium Dose

S.C. Injection

BIOLOGICAL

XXB750 High Dose

S.C. Injection

DRUG

Sacubitril/valsartan

Tablet

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-12
Primary Completion
2024-11-01
Completion
2024-11-01
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • China
  • Germany
  • Hungary
  • India
  • Italy
  • Japan
  • Portugal
  • Slovakia
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06142383 on ClinicalTrials.gov